Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bax Heather J, Chauhan Jitesh, Stavraka Chara, Santaolalla Aida, Osborn Gabriel, Khiabany Atousa, Grandits Melanie, López-Abente Jacobo, Palhares Lais C G F, Chan Wah Hak Charleen, Robinson Alexandra, Pope Amy, Woodman Natalie, Naceur-Lombardelli Cristina, Malas Sadek, Coumbe Jack E M, Nakamura Mano, Laddach Roman, Mele Silvia, Crescioli Silvia, Black Anna M, Lombardi Sara, Canevari Silvana, Figini Mariangela, Sayasneh Ahmad, Tsoka Sophia, FitzGerald Kevin, Gillett Cheryl, Pinder Sarah, Van Hemelrijck Mieke, Kristeleit Rebecca, Ghosh Sharmistha, Montes Ana, Spicer James, Karagiannis Sophia N, Josephs Debra H
Аннотация
METHODS: We evaluated sFRα longitudinally, before and during neo-adjuvant, adjuvant and palliative therapies, and tumour FRα expression status by immunohistrochemistry. The impact of free FRα on the efficacy of anti-FRα treatments was evaluated by an antibody-dependent cellular cytotoxicity assay.
RESULTS: Membrane and/or cytoplasmic FRα staining were observed in 52.7% tumours from 316 ovarian cancer patients with diverse histotypes. Circulating sFRα levels were significantly higher in patients, compared to healthy volunteers, specifically in patients sampled prior to neoadjuvant and palliative treatments. sFRα was associated with FRα cell membrane expression in the tumour. sFRα levels decreased alongside concurrent tumour burden in patients receiving standard therapies. High concentrations of sFRα partly reduced anti-FRα antibody tumour cell killing, an effect overcome by increased antibody doses.
CONCLUSIONS: sFRα may present a non-invasive marker for tumour FRα expression, with the potential for monitoring patient response to treatment. Larger, prospective studies should evaluate FRα for assessing disease burden and response to systemic treatments.